Results 31 to 40 of about 289,170 (184)

Radiogenomics prediction for MYCN amplification in Neuroblastoma: a hypothesis generating study [PDF]

Pediatric Blood & Cancer, 2021
Background: MYCN amplification represents a powerful prognostic factor in neuroblastoma (NB) and may occasionally account for intratumoral heterogeneity. Radiomics is an emerging field of advanced image analysis that aims to extract a large number of quantitative features from standard radiological images, providing valuable clinical information ...
Angela Di Giannatale, Pier Luigi Di Paolo, Davide Curione, Jacopo Lenkowicz, Antonio Napolitano, Aurelio Secinaro, Paolo Tomà, Franco Locatelli, Aurora Castellano, Luca Boldrini   +9 more
openaire   +3 more sources

MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma

Cancer Cell International, 2017
Background MYCN gene amplification is related to risk stratification. Therefore it is important to identify accurately the level of the MYCN gene as early as possible in neuroblastoma (NB); however, for patients with bone marrow (BM) metastasis who need ...
Zhi-Xia Yue, Cheng Huang, Chao Gao, Tian-Yu Xing, Shu-Guang Liu, Xing-Jun Li, Qian Zhao, Xi-Si Wang, Wen Zhao, Mei Jin, Xiao-Li Ma   +10 more
doaj   +1 more source

Age related gene DST represents an independent prognostic factor for MYCN non-amplified neuroblastoma

BMC Pediatrics, 2021
Background MYCN amplification and age are two critical prognostic factors of pediatric neuroblastoma. Previously, we had revealed the prognosis of MYCN target genes.
Haiwei Wang, Xinrui Wang, Liangpu Xu, Ji Zhang, Hua Cao   +4 more
doaj   +1 more source

MYCN mRNA degradation and cancer suppression by a selective small-molecule inhibitor in MYCN-amplified neuroblastoma

Frontiers in Oncology, 2022
Amplification of the MYCN gene leads to its overexpression at both the mRNA and protein levels. Overexpression of MYCN mRNA may also have an important role in promoting neuroblastoma (NB) beyond the translation of MYCN protein.
Tao Liu, Lubing Gu, Zhongzhi Wu, Najah Albadari, Wei Li, Muxiang Zhou   +5 more
doaj   +1 more source

Chromosome 1p36 candidate gene ZNF436 predicts the prognosis of neuroblastoma: a bioinformatic analysis

Italian Journal of Pediatrics, 2023
Background Genetic 1p deletion is reported in 30% of all neuroblastoma and is associated with the unfavorable prognosis of neuroblastoma. The expressions and prognosis of 1p candidate genes in neuroblastoma are unclear.
Haiwei Wang, Xinrui Wang, Liangpu Xu
doaj   +1 more source

Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas

Acta Neuropathologica Communications, 2021
Primary spinal cord tumors contribute to ≤ 10% of central nervous system tumors in individuals of pediatric or adolescent age. Among intramedullary tumors, spinal ependymomas make up ~ 30% of this rare tumor population.
Margaret Shatara, Kathleen M. Schieffer, Darren Klawinski, Diana L. Thomas, Christopher R. Pierson, Eric A. Sribnick, Jeremy Jones, Diana P. Rodriguez, Carol Deeg, Elizabeth Hamelberg, Stephanie LaHaye, Katherine E. Miller, James Fitch, Benjamin Kelly, Kristen Leraas, Ruthann Pfau, Peter White, Vincent Magrini, Richard K. Wilson, Elaine R. Mardis, Mohamed S. Abdelbaki, Jonathan L. Finlay, Daniel R. Boué, Catherine E. Cottrell, David R. Ghasemi, Kristian W. Pajtler, Diana S. Osorio   +26 more
doaj   +1 more source

CCNB1IP1 prevents ubiquitination‐mediated destabilization of MYCN and potentiates tumourigenesis of MYCN‐amplificated neuroblastoma

Clinical and Translational Medicine, 2023
AbstractBackgroundMYCN amplification as a common genetic alteration that correlates with a poor prognosis for neuroblastoma (NB) patients. However, given the challenge of directly targeting MYCN, indirect strategies to modulate MYCN by interfering with its cofactors are attractive in NB treatment. Although cyclin B1 interacting protein 1 (CCNB1IP1) has
Yang Zhou, Hui Yan, Qiang Zhou, Penggao Wang, Fang Yang, Ziqiao Yuan, Qianming Du, Bo Zhai   +7 more
openaire   +3 more sources

Correlation Between MYCN Gene Status and MYCN Protein Expression in Neuroblastoma: A Pilot Study To Propose the Use of MYCN Immunohistochemistry in Limited-Resource Areas

Journal of Global Oncology, 2019
PURPOSE: The most significant adverse risk factor for neuroblastoma (NB) is MYCN gene amplification, which strongly associates with high-risk disease.
Teresa Santiago, Nidale Tarek, Fouad Boulos, Caleb Hayes, Sima Jeha, Susana Raimondi, Carlos Rodriguez-Galindo   +6 more
doaj   +1 more source

An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability

Nature Communications, 2021
Neuroblastoma (NB) is often driven by MYCN amplification. Here, the authors show that the most frequent genetic lesion, gain of 17q21-ter in NB leads to overexpression of ALYREF, which forms a complex with MYCN, regulating MYCN stability via the ...
Zsuzsanna Nagy, Janith A. Seneviratne, Maxwell Kanikevich, William Chang, Chelsea Mayoh, Pooja Venkat, Yanhua Du, Cizhong Jiang, Alice Salib, Jessica Koach, Daniel R. Carter, Rituparna Mittra, Tao Liu, Michael W. Parker, Belamy B. Cheung, Glenn M. Marshall   +15 more
doaj   +1 more source

Mechanisms of embryonal tumor initiation: Distinct roles for MycN expression and MYCN amplification [PDF]

Proceedings of the National Academy of Sciences, 2004
The mechanisms causing persistence of embryonal cells that later give rise to tumors is unknown. One tumorigenic factor in the embryonal childhood tumor neuroblastoma is the MYCN protooncogene.
Loen M, Hansford, Wayne D, Thomas, Joanna M, Keating, Catherine A, Burkhart, Anne E, Peaston, Murray D, Norris, Michelle, Haber, Patricia J, Armati, William A, Weiss, Glenn M, Marshall   +9 more
openaire   +2 more sources